Table 1 Clinical, biological and densitometry data at baseline
Parameter | Whole population | Infliximab (n = 90) | No infliximab (n = 99) | P |
|---|---|---|---|---|
Age | 52.5 ± 14.2 | 50.9 ± 11.8 | 53.9 ± 15.9 | NS |
Women (n [%]) | 152 (80) | 74 (82) | 78 (79) | NS |
Disease duration (years) | 10.6 ± 9.0 | 10.2 ± 9.1 | 10.9 ± 8.9 | NS |
Patients on steroids (n [%]) | 118 (62) | 56 (62) | 62 (63) | NS |
Mean dose steroids (mg/day) | 5.30 ± 5.79 | 5.40 ± 5.75 | 5.26 ± 5.83 | NS |
DAS28 score | 5.17 ± 1.07 | 5.37 ± 0.94 | 5.00 ± 1.15 | NS |
Patients on biphosphonates (n [%]) | 35 (19) | 15 (17) | 20 (20) | NS |
Calcaemia (mmol/l) | 2.28 ± 0.13 | 2.32 ± 0.12 | 2.24 ± 0.12 | NS |
Alkaline phosphatase (U/l) | 74.6 ± 25.6 | 77.5 ± 29.5 | 72.0 ± 21.2 | NS |
Osteocalcin (ng/ml) | 19.9 ± 11.8 | 18.4 ± 9.7 | 21.2 ± 13.4 | NS |
CTX-I (pg/ml) | 446 ± 307 | 482 ± 386 | 418 ± 227 | NS |
Parathyroid hormone (pg/ml) | 30.5 ± 17.6 | 28.7 ± 15.4 | 32.0 ± 19.1 | NS |
25-hydroxycholecalciferol (ng/ml) | 19.7 ± 10.3 | 18.2 ± 10.1 | 21.2 ± 10.4 | NS |
Femoral neck BMD (g/cm2) | 0.801 ± 0.159 | 0.807 ± 0.156 | 0.797 ± 0.162 | NS |
Lumbar BMD (g/cm2) | 0.911 ± 0.143 | 0.930 ± 0.142 | 0.896 ± 0.142 | NS |
Patients with neck osteopenia (n [%]) | 96 (51) | 47 (52) | 49 (50) | NS |
Patients with lumbar osteopenia (n [%]) | 93 (49) | 40 (45) | 53 (54) | NS |
Patients with neck osteoporosis (n [%]) | 37 (20) | 18 (20) | 19 (19) | NS |
Patients with lumbar osteoporosis (n [%]) | 37 (19) | 15 (17) | 23 (23) | NS |